MedPath

Cryoanalgesia Study

Not Applicable
Active, not recruiting
Conditions
Pain, Postoperative
Interventions
Device: cryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probe
Registration Number
NCT05859061
Lead Sponsor
Northwestern University
Brief Summary

This study will investigate the feasibility of cryoanalgesia in patients undergoing cardiac surgery via a median sternotomy. Cryoanalgesia is a technique that uses extremely cold temperatures to temporarily ablate nerves and block pain signals. Cryoanalgesia has been used for decades for pain control after thoracic surgery and has been associated with decreased opioid consumption, decreased pain scores, and shorter hospital stays. The results of this study may lead to a useful alternative for pain control in cardiac surgery patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
32
Inclusion Criteria
  • Scheduled for elective CABG (coronary artery bypass graft) or single valve surgery via median sternotomy
  • Reasonable expectation to be extubated within 24 hours postop
Exclusion Criteria
  • Prior history of surgery to the thorax (sternotomy, thoracotomy, thoracoscopy)
  • Hemisternotomy approach
  • History of cold urticaria, cryoglobulinemia, Raynaud's disease, or diabetic neuropathy
  • Preoperative use of opioids
  • History of chronic pain or associated syndromes
  • Concurrent Cox maze procedure
  • Need for post-bypass mechanical circulatory support (ECMO, IABP) or open chest
  • Women who are pregnant or breastfeeding
  • Patients who are unable to consent for themselves

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
CryoanalgesiacryoICE® system (AtriCure, Inc) with CryoSphere (CryoS) probeIntraoperative analgesic administration will be at the discretion of the anesthesia provider. Once adequate hemostasis is achieved and prior to sternal wire placement and chest closure, patients will undergo cryoablation of bilateral T2 - T6 intercostal nerves. The cryoprobe will be positioned under direct visualization and ablation of the intercostal nerve will be performed 2-4 cm lateral to the internal mammary artery near the mid-clavicular line. Each cryoablation at -50°C to -70°C will be applied for 120 seconds to sustain an ablation length of 2-3 cm at each intercostal nerve (bilateral T2 - T6).
Primary Outcome Measures
NameTimeMethod
Average Daily Opioid Consumption in MME48 hours

The average daily opioid consumption in morphine milligram equivalents (MME) during the first 48 hours postoperatively serves as the study's primary outcome.

Secondary Outcome Measures
NameTimeMethod
Quality of Recovery Score48 hours/POD2 (post-operative day 2), 10 days +/- 4 days, 90 days +/- 14 days, & 180 days +/- 30 days

Scale Title: Quality of Recovery Score Scale Values: 0 - 18 Higher score means a better outcome.

Patient Satisfaction with Pain Control Regimen24 hours/POD1 (post-operative day 1), 48 hours/POD2, 10 days +/- 4 days, 90 days +/- 14 days, & 180 days +/- 30 days

Scale Title: IPO (International Pain Outcomes) Questionnaire Scale Values: 0 - 320 Higher score means a worse outcome.

Pain Severity24 hours/POD1 (post-operative day 1), 48 hours/POD2, 10 days +/- 4 days, 90 days +/- 14 days, & 180 days +/- 30 days

Scale Title: Numeric Pain Rating Scale Scale Values: 0-10 Higher score means a worse outcome.

Pain Quality24 hours/POD1 (post-operative day 1), 48 hours/POD2, 10 days +/- 4 days, 90 days +/- 14 days, & 180 days +/- 30 days

Scale Title: S-LANSS (Leeds Assessment of Neuropathic Symptoms and Signs) Pain Score Scale Values: 0-24 Higher score means a worse outcome.

Average Daily Pain Scoresduring the first 48 hours postoperatively (starting upon ICU arrival)

Scale Title: NRS (Numeric Rating Scale) Scale Values: 0-10 Higher score means a worse outcome.

Trial Locations

Locations (1)

Northwestern University

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath